AZN – AstraZeneca PLC
Float Short %
0.25
Margin Of Safety %
11
Put/Call OI Ratio
0.54
EPS Next Q Diff
EPS Last/This Y
2.29
EPS This/Next Y
0.56
Price
79.55
Target Price
92.81
Analyst Recom
1.43
Performance Q
6.08
Relative Volume
1.05
Beta
0.38
Ticker: AZN
of 1
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-08-15 | AZN | 79.18 | 0.48 | 0.13 | 127968 |
| 2025-08-18 | AZN | 79.12 | 0.47 | 0.37 | 114031 |
| 2025-08-19 | AZN | 79.59 | 0.47 | 0.45 | 116782 |
| 2025-08-20 | AZN | 80.53 | 0.48 | 0.27 | 116842 |
| 2025-08-21 | AZN | 80.46 | 0.48 | 0.42 | 117978 |
| 2025-08-22 | AZN | 80.97 | 0.49 | 1.06 | 120396 |
| 2025-08-25 | AZN | 79.7 | 0.50 | 0.94 | 120029 |
| 2025-08-26 | AZN | 80.05 | 0.50 | 0.94 | 121175 |
| 2025-08-27 | AZN | 79.93 | 0.50 | 0.61 | 122627 |
| 2025-08-28 | AZN | 80 | 0.52 | 1.72 | 129251 |
| 2025-08-29 | AZN | 79.9 | 0.53 | 0.32 | 131111 |
| 2025-09-02 | AZN | 80.21 | 0.55 | 0.34 | 131603 |
| 2025-09-03 | AZN | 82.13 | 0.54 | 1.13 | 136904 |
| 2025-09-04 | AZN | 81.78 | 0.55 | 0.56 | 140045 |
| 2025-09-05 | AZN | 81.99 | 0.55 | 0.15 | 143331 |
| 2025-09-08 | AZN | 81.55 | 0.51 | 0.40 | 136824 |
| 2025-09-09 | AZN | 81.2 | 0.52 | 0.25 | 140730 |
| 2025-09-10 | AZN | 80.82 | 0.53 | 0.37 | 140836 |
| 2025-09-11 | AZN | 81.1 | 0.53 | 1.57 | 142742 |
| 2025-09-12 | AZN | 79.57 | 0.54 | 0.64 | 146633 |
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-08-15 | AZN | 79.19 | 9.2 | 5042.6 | 4.56 |
| 2025-08-18 | AZN | 79.11 | 9.2 | 4902.3 | 4.56 |
| 2025-08-19 | AZN | 79.54 | 9.2 | 4767.8 | 4.56 |
| 2025-08-20 | AZN | 80.52 | 9.2 | 4947.1 | 4.56 |
| 2025-08-21 | AZN | 80.46 | 9.2 | 4715.7 | 4.56 |
| 2025-08-22 | AZN | 80.97 | 9.2 | 4743.1 | 4.56 |
| 2025-08-25 | AZN | 79.65 | 9.2 | 4651.0 | 4.56 |
| 2025-08-26 | AZN | 80.05 | 9.2 | 4624.0 | 4.56 |
| 2025-08-27 | AZN | 79.93 | 9.2 | 4784.3 | 4.56 |
| 2025-08-28 | AZN | 79.99 | 9.2 | 4817.8 | 4.56 |
| 2025-08-29 | AZN | 79.88 | 9.2 | 4786.2 | 4.56 |
| 2025-09-02 | AZN | 80.18 | 9.2 | 4853.1 | 4.56 |
| 2025-09-03 | AZN | 82.13 | 9.2 | 7106.6 | 4.56 |
| 2025-09-04 | AZN | 81.78 | 9.2 | 6637.8 | 4.56 |
| 2025-09-05 | AZN | 81.70 | 9.2 | 6754.3 | 4.56 |
| 2025-09-08 | AZN | 81.56 | 9.2 | 6856.8 | 4.56 |
| 2025-09-09 | AZN | 81.20 | 9.2 | 6940.9 | 4.56 |
| 2025-09-10 | AZN | 80.82 | 9.2 | 6779.3 | 4.56 |
| 2025-09-11 | AZN | 81.10 | 9.2 | 7074.8 | 4.56 |
| 2025-09-12 | AZN | 79.55 | 9.2 | 6690.7 | 4.56 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-08-15 | AZN | 0 | 1.15 | 0.17 |
| 2025-08-18 | AZN | 0 | 1.36 | 0.17 |
| 2025-08-19 | AZN | 0.00 | 1.36 | 0.17 |
| 2025-08-20 | AZN | 0.00 | 1.36 | 0.17 |
| 2025-08-21 | AZN | 0.00 | 1.36 | 0.17 |
| 2025-08-22 | AZN | 0.00 | 1.36 | 0.17 |
| 2025-08-25 | AZN | 0.00 | -0.98 | 0.17 |
| 2025-08-26 | AZN | 0.00 | -0.98 | 0.17 |
| 2025-08-27 | AZN | 0.00 | -0.98 | 0.20 |
| 2025-08-28 | AZN | 0.00 | -0.98 | 0.20 |
| 2025-08-29 | AZN | 0.00 | -0.98 | 0.20 |
| 2025-09-02 | AZN | 0.00 | -0.99 | 0.20 |
| 2025-09-03 | AZN | 0.00 | -0.99 | 0.20 |
| 2025-09-04 | AZN | 0.00 | -0.99 | 0.20 |
| 2025-09-05 | AZN | 0.00 | -0.99 | 0.20 |
| 2025-09-08 | AZN | 0.00 | -1.13 | 0.20 |
| 2025-09-09 | AZN | 0.00 | -1.13 | 0.20 |
| 2025-09-10 | AZN | 0.00 | -1.13 | 0.20 |
| 2025-09-11 | AZN | 0.00 | -1.13 | 0.25 |
| 2025-09-12 | AZN | 0.00 | -1.13 | 0.25 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
1.09
Avg. EPS Est. Current Quarter
1.14
Avg. EPS Est. Next Quarter
1.09
Insider Transactions
Institutional Transactions
-1.13
Beta
0.38
Average Sales Estimate Current Quarter
14750
Average Sales Estimate Next Quarter
15388
Fair Value
88.23
Quality Score
92
Growth Score
94
Sentiment Score
81
Actual DrawDown %
9.3
Max Drawdown 5-Year %
-27.9
Target Price
92.81
P/E
29.84
Forward P/E
15.41
PEG
2.53
P/S
4.36
P/B
5.52
P/Free Cash Flow
21.46
EPS
2.67
Average EPS Est. Cur. Y
4.56
EPS Next Y. (Est.)
5.11
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
14.71
Relative Volume
1.05
Return on Equity vs Sector %
-6.3
Return on Equity vs Industry %
-14.9
EPS 1 7Days Diff
EPS 1 30Days Diff
EBIT Estimation
6690.7
Astrazeneca PLCSector: Healthcare
Industry: Drug Manufacturers - General
Employees: 94300
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Crestor, Seloken, Lokelma, Roxadustat, Andexxa, Wainua, Symbicort, Fasenra, Pulmicort, Breztri/Trixeo, Saphnelo, Tezspire, Airsupra, Ultomiris, Soliris, Strensiq, Koselugo, Kanuma, Atacand, Plendil, Modip, Splendil, Munobal, Flodil, Komboglyze, Qtern, Byetta, XIGDUO, Accolate, Accoleit, Vanticon, Beyfortus, Synagis, FluMist, tixagevimab and cilgavimab, and sipavibart. It also provides Bricanyl Respules, Eklira Genuair/Tudorza/Bretaris, Bricanyl Turbuhaler, Rhinocort, Bevespi Aerosphere, Daliresp/Daxas, Oxis Turbuhaler, Breztri Aerosphere, Duaklir Genuair, Kavigale, Evusheld, Fluenz/FluMist, and Voydeya. The company offers its products for ocology, cardiovascular, renal and metabolism, respiratory & immunology, vaccines and immune, and therapies rare diseases. It serves primary and specialty care physicians through distributors and local representative offices in the United Kingdom, the United States, Europe, and Asia. It has a strategic agreement with Tempus to develop the largest multimodal foundation model in oncology. The company has a collaboration agreement with IonQ, Inc. for the development of quantum-accelerated computational chemistry workflow for healthcare, life sciences, and chemistry; a strategic research collaboration with CSPC Pharmaceutical Group Limited to advance the discovery and development of novel oral candidates, with the potential to treat diseases across multiple indications; and collaboration Revna Biosciences for lung cancer treatment. AstraZeneca PLC was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
stock quote shares AZN – AstraZeneca PLC Stock Price stock today
news today AZN – AstraZeneca PLC stock forecast ,stock prediction 2023 2024 2025
marketwatch AZN – AstraZeneca PLC yahoo finance google finance
stock history AZN – AstraZeneca PLC invest stock market
stock prices AZN premarket after hours
ticker AZN fair value insiders trading